Resveratrol demonstrates significant renoprotective effects across chronic kidney disease, diabetic nephropathy, renal fibrosis, and drug-induced nephrotoxicity by simultaneously targeting oxidative stress, inflammation, angiogenesis, and apoptosis pathways. Clinical investigations have shown improvements in renal function markers, while the compound's excellent safety profile supports therapeutic potential. This finding represents a notable consolidation of evidence for resveratrol's kidney benefits, particularly relevant given chronic kidney disease affects over 850 million people globally with limited treatment options. The compound's multi-pathway approach addresses the complex pathophysiology of kidney disease more comprehensively than single-target therapies. However, most supporting evidence likely derives from preclinical studies, and resveratrol's notorious bioavailability challenges remain unresolved despite advanced formulation strategies mentioned. The therapeutic doses required may exceed what's achievable through dietary sources like red wine or grapes. While promising, this represents incremental progress in a well-studied compound rather than breakthrough science, and robust clinical trials with standardized formulations are essential before resveratrol can be considered a viable nephroprotective intervention.